PL3411473T3 - Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii - Google Patents

Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii

Info

Publication number
PL3411473T3
PL3411473T3 PL17715658T PL17715658T PL3411473T3 PL 3411473 T3 PL3411473 T3 PL 3411473T3 PL 17715658 T PL17715658 T PL 17715658T PL 17715658 T PL17715658 T PL 17715658T PL 3411473 T3 PL3411473 T3 PL 3411473T3
Authority
PL
Poland
Prior art keywords
immunotherapy
stem cells
mesenchymal stem
cancer activity
cells enhancing
Prior art date
Application number
PL17715658T
Other languages
English (en)
Polish (pl)
Inventor
Felix Hermann
Christine Günther
Ulf GEUMANN
Original Assignee
JunctuCell Biomed Manufacturing GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JunctuCell Biomed Manufacturing GmbH filed Critical JunctuCell Biomed Manufacturing GmbH
Publication of PL3411473T3 publication Critical patent/PL3411473T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17715658T 2016-04-01 2017-03-31 Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii PL3411473T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16163557 2016-04-01
EP16176185 2016-06-24
EP17715658.5A EP3411473B1 (en) 2016-04-01 2017-03-31 Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
PCT/EP2017/057679 WO2017167959A1 (en) 2016-04-01 2017-03-31 Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy

Publications (1)

Publication Number Publication Date
PL3411473T3 true PL3411473T3 (pl) 2021-05-04

Family

ID=58489308

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17715658T PL3411473T3 (pl) 2016-04-01 2017-03-31 Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii

Country Status (10)

Country Link
US (2) US20190030152A1 (enExample)
EP (2) EP3730607A1 (enExample)
JP (1) JP6971986B2 (enExample)
KR (1) KR20190003456A (enExample)
CN (1) CN108884440A (enExample)
AU (2) AU2017242899A1 (enExample)
CA (1) CA3008352A1 (enExample)
ES (1) ES2823162T3 (enExample)
PL (1) PL3411473T3 (enExample)
WO (1) WO2017167959A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606540A1 (en) * 2017-04-07 2020-02-12 Cynata Therapeutics Limited Method for treating a side effect of chimeric antigen receptor (car) t cell therapy
AU2018285953A1 (en) * 2017-06-16 2020-01-16 Cynata Therapeutics Limited Method for treating a side effect of immunotherapy
WO2019104037A1 (en) * 2017-11-22 2019-05-31 The Brigham And Women's Hospital, Inc. Msc-expressed immunomodulators in combination with car-t for cancer therapy
US20220133791A1 (en) * 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
KR20220137630A (ko) * 2020-02-05 2022-10-12 워싱턴 유니버시티 Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
WO2022155585A2 (en) * 2021-01-15 2022-07-21 City Of Hope Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereof
CN112980888B (zh) * 2021-02-22 2023-04-14 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 分泌il-6抗体/cd20抗体的间充质干细胞、构建方法及其应用
EP4180049A1 (en) * 2021-11-16 2023-05-17 Ostravska univerzita Therapeutic composition for cancer treatment
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
BRPI0811906A2 (pt) 2007-05-24 2014-11-18 Apceth Gmbh & Co Kg Composições e métodos relacionados a célula-tronco cd34
US8557578B2 (en) 2009-12-23 2013-10-15 Apceth Gmbh & Co. Kg Expansion medium for CD34-negative stem cells
CN102641298B (zh) * 2012-05-15 2014-03-05 祁岩超 一种预防和治疗肿瘤的效应细胞组合及其制备方法
WO2014087217A1 (en) * 2012-12-03 2014-06-12 Subhadra Dravida Allogenic mesendritic vector for ovarian cancer
AU2013370932B2 (en) * 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
CA2956987C (en) * 2014-08-18 2023-03-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
TW201619133A (zh) * 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物

Also Published As

Publication number Publication date
EP3730607A1 (en) 2020-10-28
ES2823162T3 (es) 2021-05-06
AU2023237078A1 (en) 2023-10-12
CA3008352A1 (en) 2017-10-05
AU2017242899A1 (en) 2018-07-05
JP6971986B2 (ja) 2021-11-24
JP2019509715A (ja) 2019-04-11
US20190030152A1 (en) 2019-01-31
CN108884440A (zh) 2018-11-23
US20230063829A1 (en) 2023-03-02
EP3411473B1 (en) 2020-07-08
EP3411473A1 (en) 2018-12-12
KR20190003456A (ko) 2019-01-09
WO2017167959A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
IL250689A0 (en) Resetting pluripotent stem cells
IL262458A (en) Methods for selectively modulating the activity of distinct subtypes of cells
EP3624810A4 (en) NANO-ACTIVATED IMMUNOTHERAPY FOR CANCER DISEASES
IL257009A (en) Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
PL3411473T3 (pl) Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii
EP3510145A4 (en) Immune cells derived from induced pluripotent stem cell
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
DK3523423T3 (da) Fremgangsmåder til målrettet differentiering af pluripotente stamceller til hla homozygote immunceller
HUE053101T2 (hu) Javított T-sejt-készítmények
DK3134095T3 (da) Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
LT3556777T (lt) Daugiaspecifiniai antikūno konstruktai
BR112017009540A2 (pt) biorreator usando macroalgas
EP3461890C0 (en) TOTAL FERMENTATION OF OLIGOSACCHARIDES
DK3455344T3 (da) Hæmatopoietiske stam-/Progenitorceller
LT3628680T (lt) Komplemento aktyvumo moduliavimas
DK3164414T3 (da) Antistoffer for IL-15
EP3221446C0 (en) IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS
DK3577219T3 (da) Alfa-amylase-varianter
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP3037812C0 (en) ENZYME ELECTRODE
DK3365107T3 (da) Cellekultur
DK3157504T3 (da) Stamcellestimulerende sammensætninger
KR20180085018A (ko) 조혈 줄기/전구 세포의 확장된 집단의 용도
BR112016019822A2 (pt) Determinação enzimática de hba1c
DK3167052T3 (da) P450-bm3-varianter med forbedret aktivitet